These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 17032651)
41. An oncogenic epidermal growth factor receptor signals via a p21-activated kinase-caldesmon-myosin phosphotyrosine complex. McManus MJ; Boerner JL; Danielsen AJ; Wang Z; Matsumura F; Maihle NJ J Biol Chem; 2000 Nov; 275(45):35328-34. PubMed ID: 10954714 [TBL] [Abstract][Full Text] [Related]
42. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Lidke DS; Nagy P; Heintzmann R; Arndt-Jovin DJ; Post JN; Grecco HE; Jares-Erijman EA; Jovin TM Nat Biotechnol; 2004 Feb; 22(2):198-203. PubMed ID: 14704683 [TBL] [Abstract][Full Text] [Related]
43. Epidermal growth factor receptors containing a single tyrosine in their C-terminal tail bind different effector molecules and are signaling-competent. Gill K; Macdonald-Obermann JL; Pike LJ J Biol Chem; 2017 Dec; 292(50):20744-20755. PubMed ID: 29074618 [TBL] [Abstract][Full Text] [Related]
44. A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration in vitro and xenograft tumor growth in vivo. Xu R; Povlsen GK; Soroka V; Bock E; Berezin V Cell Oncol; 2010 Jan; 32(4):259-74. PubMed ID: 20364069 [TBL] [Abstract][Full Text] [Related]
45. Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction. Borer JG; Park JM; Atala A; Nguyen HT; Adam RM; Retik AB; Freeman MR Lab Invest; 1999 Nov; 79(11):1335-45. PubMed ID: 10576204 [TBL] [Abstract][Full Text] [Related]
46. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. Wilson KJ; Mill CP; Gallo RM; Cameron EM; VanBrocklin H; Settleman J; Riese DJ Biochem J; 2012 Apr; 443(1):133-44. PubMed ID: 22216880 [TBL] [Abstract][Full Text] [Related]
47. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
48. Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells. Hiroshima M; Saeki Y; Okada-Hatakeyama M; Sako Y Proc Natl Acad Sci U S A; 2012 Aug; 109(35):13984-9. PubMed ID: 22891299 [TBL] [Abstract][Full Text] [Related]
49. Expression of the EGF receptor family members ErbB2, ErbB3, and ErbB4 in germinal zones of the developing brain and in neurosphere cultures containing CNS stem cells. Kornblum HI; Yanni DS; Easterday MC; Seroogy KB Dev Neurosci; 2000; 22(1-2):16-24. PubMed ID: 10657694 [TBL] [Abstract][Full Text] [Related]
50. Ligand discrimination in signaling through an ErbB4 receptor homodimer. Sweeney C; Lai C; Riese DJ; Diamonti AJ; Cantley LC; Carraway KL J Biol Chem; 2000 Jun; 275(26):19803-7. PubMed ID: 10867024 [TBL] [Abstract][Full Text] [Related]
51. Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with colorectal cancer. Nagaoka T; Kitaura K; Miyata Y; Kumagai K; Kaneda G; Kanazawa H; Suzuki S; Hamada Y; Suzuki R Mol Med Rep; 2016 Apr; 13(4):3514-20. PubMed ID: 26935861 [TBL] [Abstract][Full Text] [Related]
52. Prognostic value of ERBB family mRNA expression in breast carcinomas. Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037 [TBL] [Abstract][Full Text] [Related]
53. Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3. Walker F; Hibbs ML; Zhang HH; Gonez LJ; Burgess AW Growth Factors; 1998; 16(1):53-67. PubMed ID: 9777370 [TBL] [Abstract][Full Text] [Related]
54. Novel Pituitary Actions of Epidermal Growth Factor: Receptor Specificity and Signal Transduction for Hu Q; Xu S; Ye C; Jia J; Zhou L; Hu G Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635309 [TBL] [Abstract][Full Text] [Related]
55. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Ogiso H; Ishitani R; Nureki O; Fukai S; Yamanaka M; Kim JH; Saito K; Sakamoto A; Inoue M; Shirouzu M; Yokoyama S Cell; 2002 Sep; 110(6):775-87. PubMed ID: 12297050 [TBL] [Abstract][Full Text] [Related]
57. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. Kochupurakkal BS; Harari D; Di-Segni A; Maik-Rachline G; Lyass L; Gur G; Kerber G; Citri A; Lavi S; Eilam R; Chalifa-Caspi V; Eshhar Z; Pikarsky E; Pinkas-Kramarski R; Bacus SS; Yarden Y J Biol Chem; 2005 Mar; 280(9):8503-12. PubMed ID: 15611079 [TBL] [Abstract][Full Text] [Related]
58. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization. Li Y; Macdonald-Obermann J; Westfall C; Piwnica-Worms D; Pike LJ J Biol Chem; 2012 Sep; 287(37):31116-25. PubMed ID: 22822073 [TBL] [Abstract][Full Text] [Related]
59. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016 [TBL] [Abstract][Full Text] [Related]
60. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Jin P; Zhang J; Beryt M; Turin L; Brdlik C; Feng Y; Bai X; Liu J; Jorgensen B; Shepard HM Mol Med; 2009; 15(1-2):11-20. PubMed ID: 19048033 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]